H. Gerber

Molecular Biology · Nature Medicine · 2002–2008

A researcher in the Science corpus: 10 papers; trusts 5 researchers and is trusted by 11 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 72 citations into it; #3,392 of 17,773 by trust here, #2,080 by citations
• Cancer Research — 38 citations into it; #277 of 1,780 by trust here, #260 by citations
• Oncology — 32 citations into it; #296 of 1,698 by trust here, #382 by citations
• Pulmonary and Respiratory Medicine — 14 citations into it
• Cell Biology — 11 citations into it
• Cellular and Molecular Neuroscience — 5 citations into it

Whom H. Gerber trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. N. Ferrara
2. Rakesh K. Jain
3. R. Kerbel
4. G. Klement

Who trusts H. Gerber overall

1. N. Ferrara
2. R. Apte
3. Y. Fouad
4. J. Joyce
5. Alicia S. Chung
6. A. Adamis
7. Sunyoung Lee
8. Zhiya Yu
9. Peter Carmeliet
10. Kai Hu

Papers from H. Gerber's perspective

Ordered by how strongly the researchers H. Gerber trusts endorse each paper. Same corpus, a different order for every researcher.

1. Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells (Journal of Experimental Medicine)
2. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis (Nature Cell Biology)
3. Clinical translation of angiogenesis inhibitors (Nature Reviews. Cancer)
4. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 (Nature Medicine)
5. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. (Journal of Clinical Oncology)
6. Molecular mechanisms of drug resistance (Journal of Pathology)
7. Tumor angiogenesis (Advances in Cancer Research)
8. The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
9. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (Cancer Research)
10. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)

Their papers

• The biology of VEGF and its receptors (2003) — 9,751 citations
• Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004) — 2,638 citations
• Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells (2007) — 887 citations
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005) — 645 citations
• VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism (2002) — 755 citations
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. (2007) — 954 citations
• VEGF inhibition and renal thrombotic microangiopathy. (2008) — 694 citations
• Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. (2003) — 1,304 citations
• HIF-1alpha is essential for myeloid cell-mediated inflammation. (2003) — 1,025 citations
• Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 (2003) — 688 citations